<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03367910</url>
  </required_header>
  <id_info>
    <org_study_id>201708204</org_study_id>
    <nct_id>NCT03367910</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation (FMT) for MDRO UTI</brief_title>
  <official_title>Fecal Microbiota Transplantation Using RBX2660 for the Prevention of Recurrent Urinary Tract Infections Due to Multidrug Resistant Organisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rush University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rebiotix Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and impact of fecal microbiota&#xD;
      transplantation (FMT) on the fecal and urine microbiome, urine metabolome, risk of recurrent&#xD;
      urinary tract infection (UTI), and persistent multidrug resistant organism (MDRO)&#xD;
      colonization of patients with a history of recurrent MDRO UTIs. This is an open label phase&#xD;
      1-2 study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multidrug resistant organism (MDRO) infections are increasingly common. The most common type&#xD;
      of infection caused by MDROs is urinary tract infections (UTIs). Many MDROs are inhabitants&#xD;
      of the colon, and MDROs can contaminate the periurethral area and migrate to the bladder.&#xD;
      Patients with MDRO UTI frequently experience multiple relapses and hospitalizations, which&#xD;
      both increase the individual's morbidity and mortality and leads to additional MDRO&#xD;
      nosocomial spread. There are few options available to prevent MDRO UTIs, and there are&#xD;
      limited strategies to identify patients at risk for recurrent MDRO UTI and prevent or reverse&#xD;
      MDRO colonization. A potential novel method to reverse MDRO colonization and prevent&#xD;
      recurrent UTI would be by repopulating the gut microbiome with &quot;healthy&quot; microbiota by fecal&#xD;
      microbiota transplantation (FMT).&#xD;
&#xD;
      In this study, participants with a history of severe, recurrent MDRO UTI will receive FMT.&#xD;
      Participants will submit stool and urine specimens pre- and post-FMT, and the effect of FMT&#xD;
      on the participants' fecal and urine microbiome, urine metabolome, persistent MDRO&#xD;
      colonization, and risk of recurrent UTI will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 8, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants with eligible MDRO UTIs will receive FMT.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FMT safety: adverse events during and after FMT</measure>
    <time_frame>Six months post-FMT</time_frame>
    <description>The number, types, severity, and relation of adverse events to study procedures or product will be analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent UTI</measure>
    <time_frame>Six months post-FMT</time_frame>
    <description>Risk of recurrent UTI post-FMT will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDRO colonization</measure>
    <time_frame>Six months post-FMT</time_frame>
    <description>Stool and urine specimens will be analyzed pre- and post-FMT to evaluate the impact of FMT on MDRO colonization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>FMT for MDRO UTI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with eligible MDRO UTIs will receive FMT (150mL of RBX2660) via enema.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fecal microbiota transplant</intervention_name>
    <description>150mL of FMT product RBX2660 delivered via enema</description>
    <arm_group_label>FMT for MDRO UTI</arm_group_label>
    <other_name>Stool transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 years old.&#xD;
&#xD;
          -  Outpatient status at time of FMT.&#xD;
&#xD;
          -  History of at least three recurrent UTIs due to an MDRO; at least two recurrent,&#xD;
             severe infections due to MDRO requiring hospitalization; or at least two recurrent&#xD;
             infections due to MDRO for which only antimicrobials with rate limiting toxicities&#xD;
             (see above) are available.&#xD;
&#xD;
          -  Be without active infection due to the MDRO at the time of FMT.&#xD;
&#xD;
          -  Not be receiving antimicrobials (therapeutic or suppressive) within 48 hours of FMT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Inpatient status at time of FMT&#xD;
&#xD;
          -  Ineligible UTI&#xD;
&#xD;
          -  &gt;1 organism in urine (other than minimal contaminants)&#xD;
&#xD;
          -  Decline to participate&#xD;
&#xD;
          -  Recurrent Clostridium difficile infection&#xD;
&#xD;
          -  Presence of intra-abdominal devises&#xD;
&#xD;
          -  Neutropenia (ANC &lt;500 mm3)&#xD;
&#xD;
          -  Intestinal mucosal disruption&#xD;
&#xD;
          -  Unlikely to survive 6 months&#xD;
&#xD;
          -  Pregnancy or unwillingness to use contraceptives&#xD;
&#xD;
          -  Short gut syndrome&#xD;
&#xD;
          -  Use of medications that affect intestinal motility&#xD;
&#xD;
          -  Gastrointestinal motility disorder&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Recent abdominal surgery&#xD;
&#xD;
          -  Active typhlitis&#xD;
&#xD;
          -  Active diverticulitis&#xD;
&#xD;
          -  Current gastrointestinal graft versus host disease&#xD;
&#xD;
          -  HIV with lack of antiretroviral therapy (ART)&#xD;
&#xD;
          -  CD4 count &lt;200 mm3&#xD;
&#xD;
          -  Peritoneal dialysis&#xD;
&#xD;
          -  Cirrhosis with ascites&#xD;
&#xD;
          -  Active intra-abdominal malignancy&#xD;
&#xD;
          -  Presence of chronic indwelling foley catheter, chronic suprapubic catheter, or ileal&#xD;
             conduit&#xD;
&#xD;
          -  Active hepatitis C&#xD;
&#xD;
          -  Active hepatitis B&#xD;
&#xD;
          -  Presence of ureteral stent&#xD;
&#xD;
          -  Active kidney stone that is believed to be a persistent source of bacterial&#xD;
             colonization&#xD;
&#xD;
          -  Any condition where the investigator feels the risks of FMT outweigh the benefits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Dubberke, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary tract infection</keyword>
  <keyword>Multidrug resistant organism</keyword>
  <keyword>Fecal microbiota transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

